[Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update].
Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or surgery has provided a benefit regarding survival free progression. The place of hormone therapy in localized prostate cancer is not well defined and the debate is still ongoing, especially in case of biochemical recurrence after irradiation or radical prostatectomy and even in neoadjuvant cases. Additional and further studies are ongoing and are strongly needed to establish new guidelines. Nevertheless, hormone therapy is not restricted any more to palliative cases and is part of the current therapeutic arsenal of the urologist for high risk localized and/or locally advanced prostate cancers.
Drouin
S-J
SJ
Services d'Urologie Hôpital Pitié-Salpétrière, Groupe Hospitalo-Universitaire Est, 47-83 bd de l'Hôpital, 75651 Paris cedex 13, France.
Rouprêt
M
M
Davin
J-L
JL
Soulié
M
M
D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy / Q000379:methods*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D016019:Survival Analysis; D013997:Time Factors
D007987:Gonadotropin-Releasing Hormone